Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation.
Jonas
S
S
Department of Surgery, Virchow Medical Center, Humboldt University, Berlin, Germany.
Bechstein
W O
WO
Rayes
N
N
Neuhaus
R
R
Guckelberger
O
O
Tullius
S G
SG
Schmidt
G
G
Riess
H
H
Lobeck
H
H
Vogl
T
T
Neuhaus
P
P
D006528:Carcinoma, Hepatocellular / Q000453:epidemiology; D016572:Cyclosporine / Q000627:therapeutic use; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000601:surgery; D006526:Hepatitis C / Q000601:surgery; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000601:surgery; D008113:Liver Neoplasms / Q000453:epidemiology; D016031:Liver Transplantation / Q000276:immunology*; D008223:Lymphoma / Q000453:epidemiology; D009369:Neoplasms / Q000453:epidemiology* / Q000209:etiology; D011183:Postoperative Complications; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus